HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

References

• Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–447. doi:10.1038/s41580-022-00566-8
   PubMed Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54. doi:10.1016/j.gpb.2015.09.006
   PubMed Web of Science ®Google Scholar
• Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43. doi:10.1186/s12943-016-0530-6
   PubMed Web of Science ®Google Scholar
• Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–669. doi:10.1534/genetics.112.146704
   PubMed Web of Science ®Google Scholar
• Li J, Tian H, Yang J, Gong Z. Long noncoding RNAs regulate cell growth, proliferation, and apoptosis. DNA Cell Biol. 2016;35(9):459–470. doi:10.1089/dna.2015.3187
   PubMed Web of Science ®Google Scholar
• Ou C, He X, Liu Y, Zhang X. lncRNA cytoskeleton regulator RNA (CYTOR): diverse functions in metabolism, inflammation and tumorigenesis, and potential applications in precision oncology. Genes Dis. 2023;10(2):415–429. doi:10.1016/j.gendis.2021.08.012
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Y, Cong Q, Xu Q. Non‑coding RNAs: role of miRNAs and lncRNAs in the regulation of autophagy in hepatocellular carcinoma (Review). Oncol Rep. 2023;49(6). doi:10.3892/or.2023.8550
   Web of Science ®Google Scholar
• Kudriashov V, Sufianov A, Mashkin A, et al. The role of long non-coding RNAs in carbohydrate and fat metabolism in the liver. Non-Coding RNA Res. 2023;8(3):294–301. doi:10.1016/j.ncrna.2023.03.003
   PubMed Web of Science ®Google Scholar
• Sanya DRA, Onésime D. Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer. Hum Cell. 2023:1–30. doi:10.1007/s13577-023-00915-5
   PubMed Web of Science ®Google Scholar
• Hu Q, Li Y, Li D, et al. Amino acid metabolism regulated by lncRNAs: the propellant behind cancer metabolic reprogramming. Cell Commun Signal. 2023;21(1):87.
   PubMed Web of Science ®Google Scholar
• Zhu W, Chen X, Guo X, et al. Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer. Cancer Res. 2022;82(5):805–818. doi:10.1158/0008-5472.CAN-21-1179
   PubMed Web of Science ®Google Scholar
• Zhang TT, Chen HP, Yu SY, Zhao SP. LncRNA HOXC-AS3 overexpression inhibits TGF-β2-induced colorectal cancer cell migration and invasion by sponging miR-1269. Hum Exp Toxicol. 2022;41:9603271221093630. doi:10.1177/09603271221093630
   Web of Science ®Google Scholar
• Wan L, Cheng Z, Sun Q, Jiang K. LncRNA HOXC-AS3 increases non-small cell lung cancer cell migration and invasion by sponging premature miR-96. Expert Rev Respir Med. 2022;16(5):587–593.
   PubMed Web of Science ®Google Scholar
• Su H, Fan G, Huang J, Qiu X. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis. 2022;13(4):307. doi:10.1038/s41419-022-04723-x
   PubMed Web of Science ®Google Scholar
• Su C, Wang W, Mo J, et al. Long noncoding RNA HOXC-AS3 interacts with CDK2 to promote proliferation in hepatocellular carcinoma. Biomarker Res. 2022;10(1):65. doi:10.1186/s40364-022-00411-2
   PubMed Web of Science ®Google Scholar
• Li Y, Peng L, Cao X, et al. The long non-coding RNA HOXC-AS3 promotes glioma progression by sponging miR-216 to regulate F11R expression. Front Oncol. 2022;12:845009. doi:10.3389/fonc.2022.845009
   PubMedGoogle Scholar
• Zhang E, He X, Zhang C, et al. A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1. Genome Biol. 2018;19(1):154. doi:10.1186/s13059-018-1523-0
   PubMed Web of Science ®Google Scholar
• Yang Z, Hu T. Long noncoding RNA HOXC-AS3 facilitates the progression of invasive mucinous adenocarcinomas of the lung via modulating FUS/FOXM1. In Vitro Cell Dev Biol Anim. 2020;56(1):15–23. doi:10.1007/s11626-019-00414-8
   PubMed Web of Science ®Google Scholar
• Su J, Yu B, Zhang C, et al. Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer. Am J Transl Res. 2020;12(10):6335–6350.
   PubMed Web of Science ®Google Scholar
• Shi SH, Jiang J, Zhang W, et al. A novel lncRNA HOXC-AS3 acts as a miR-3922-5p sponge to promote breast cancer metastasis. Cancer Invest. 2020;38(1):1–12. doi:10.1080/07357907.2019.1695816
   PubMed Web of Science ®Google Scholar
• Wang X, Sun Y, Xu T, et al. HOXB13 promotes proliferation, migration, and invasion of glioblastoma through transcriptional upregulation of lncRNA HOXC-AS3. J Cell Biochem. 2019;120(9):15527–15537. doi:10.1002/jcb.28819
   PubMed Web of Science ®Google Scholar
• Li B, Han H, Song S, et al. HOXC10 regulates osteogenesis of mesenchymal stromal cells through interaction with its natural antisense transcript lncHOXC-AS3. Stem Cells. 2019;37(2):247–256. doi:10.1002/stem.2925
   PubMed Web of Science ®Google Scholar
• Xu Y, Ren Z, Wang X, Ren M. The lncRNA HOXA11-AS acts as a tumor promoter in breast cancer through regulation of the miR-125a-5p/TMPRSS4 axis. J Gene Med. 2022;24(5):e3413. doi:10.1002/jgm.3413
   PubMed Web of Science ®Google Scholar
• Wei C, Zhang X, Peng D, et al. LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway. Cell Death Dis. 2022;13(11):942. doi:10.1038/s41419-022-05393-5
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan W, Zhou D, Jin G, Cheng X. Long non‑coding RNA HOXA11‑AS accelerates cell proliferation and epithelial‑mesenchymal transition in hepatocellular carcinoma by modulating the miR‑506‑3p/Slug axis. Int J Mol Med. 2020;46(5):1805–1815. doi:10.3892/ijmm.2020.4715
   PubMed Web of Science ®Google Scholar
• Xu HW, Chen YR, Ouyang SS, Li P, Wang MQ, Zhu SL. HOTAIR plays an oncogenic role in gastric cancer through microRNA and SNP. Neoplasma. 2021;68(3):465–471. doi:10.4149/neo_2021_210127N138
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Dashti S, Farsi M, Taheri M. HOX transcript antisense RNA: an oncogenic lncRNA in diverse malignancies. Exp Mol Pathol. 2021;118:104578. doi:10.1016/j.yexmp.2020.104578
   PubMed Web of Science ®Google Scholar
• Rajagopal T, Talluri S, Akshaya RL, Dunna NR. HOTAIR LncRNA: a novel oncogenic propellant in human cancer. Clin Chim Acta. 2020;503:1–18. doi:10.1016/j.cca.2019.12.028
   PubMed Web of Science ®Google Scholar
• Liu FT, Qiu C, Luo HL, et al. The association of HOTAIR expression with clinicopathological features and prognosis in gastric cancer patients. Panminerva Med. 2016;58(2):167–174.
   PubMed Web of Science ®Google Scholar
• Martens L, Rühle F, Witten A, et al. A genetic variant alters the secondary structure of the lncRNA H19 and is associated with dilated cardiomyopathy. RNA Biol. 2021;18(sup1):409–415. doi:10.1080/15476286.2021.1952756
   PubMedGoogle Scholar
• Lorenz R, Bernhart SH, Höner Zu Siederdissen C, et al. ViennaRNA Package 2.0. Algorithms Mol Biol. 2011;6(1):26. doi:10.1186/1748-7188-6-26
   PubMed Web of Science ®Google Scholar
• Dong Y, Li X, Lin Z, et al. HOXC-AS1-MYC regulatory loop contributes to the growth and metastasis in gastric cancer. J Exper Clin Cancer Res. 2019;38(1):502. doi:10.1186/s13046-019-1482-7
   PubMed Web of Science ®Google Scholar
• Zhou LL, Jiao Y, Chen HM, et al. Differentially expressed long noncoding RNAs and regulatory mechanism of LINC02407 in human gastric adenocarcinoma. World J Gastroenterol. 2019;25(39):5973–5990. doi:10.3748/wjg.v25.i39.5973
   PubMed Web of Science ®Google Scholar
• Xu YZ, Chen FF, Zhang Y, Liang H, Li XJ, He C. Identification of potential long noncoding RNA associated with nasopharyngeal carcinoma using deep sequencing. J Int Med Res. 2019;47(7):3271–3281. doi:10.1177/0300060519845973
   PubMed Web of Science ®Google Scholar
• Yang B, Sun L, Liang L. LncRNA HOXC-AS3 suppresses the formation of mature miR-96 in ovarian cancer cells to promote cell proliferation. Reprod Sci. 2021;28(8):2342–2349. doi:10.1007/s43032-021-00500-x
   PubMed Web of Science ®Google Scholar
• Zhao R, Song J, Jin Y, Liu Y. Long noncoding RNA HOXC-AS3 enhances the progression of cervical cancer via activating ErbB signaling pathway. J Mol Histol. 2021;52(5):991–1006. doi:10.1007/s10735-021-10007-z
   PubMed Web of Science ®Google Scholar
• Enteghami M, Ghorbani M, Zamani M, Galehdari H. HOXC10 is significantly overexpressed in colorectal cancer. Biomed Rep. 2020;13(3):18. doi:10.3892/br.2020.1325
   PubMed Web of Science ®Google Scholar
• Yu Y, Nangia-Makker P, Farhana L, Majumdar APN. A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):155. doi:10.1186/s12943-017-0725-5
   PubMed Web of Science ®Google Scholar
• Jin Z, Li H, Long Y, Liu R, Ni X. MicroRNA-1269 is downregulated in glioblastoma and its maturation is regulated by long non-coding RNA SLC16A1 antisense RNA 1. Bioengineered. 2022;13(5):12749–12759. doi:10.1080/21655979.2022.2070581
   PubMed Web of Science ®Google Scholar
• Li X, Zhu L, Luo Y. Long non-coding RNA HLA-F antisense RNA 1 inhibits the maturation of microRNA-613 in polycystic ovary syndrome to promote ovarian granulosa cell proliferation and inhibit cell apoptosis. Bioengineered. 2022;13(5):12289–12297. doi:10.1080/21655979.2022.2070965
   PubMed Web of Science ®Google Scholar
• Zhang H, Hao Y, Yang A, et al. TGFB3-AS1 promotes Hcy-induced inflammation of macrophages via inhibiting the maturity of miR-144 and upregulating Rap1a. Mol Ther Nucleic Acids. 2021;26:1318–1335. doi:10.1016/j.omtn.2021.10.031
   PubMedGoogle Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–358. doi:10.1016/j.cell.2011.07.014
   PubMed Web of Science ®Google Scholar
• Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–1121. doi:10.1158/2159-8290.CD-13-0202
   PubMed Web of Science ®Google Scholar
• Dhawan A. Mathematical modeling of ceRNA-based interactions. Methods Mol Biol. 2021;2324:105–114.
   PubMedGoogle Scholar
• Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther. 2022;29(12):1866–1877. doi:10.1038/s41417-022-00487-w
   PubMed Web of Science ®Google Scholar
• Alsayed R, Sheikhan K, Alam MA, et al. Epigenetic programing of cancer stemness by transcription factors-non-coding RNAs interactions. Semin Cancer Biol. 2023;92:74–83. doi:10.1016/j.semcancer.2023.04.005
   PubMed Web of Science ®Google Scholar
• Khan M, Hou S, Chen M, Lei H. Mechanisms of RNA export and nuclear retention. Wiley Interdiscip Rev RNA. 2023;14(3):e1755. doi:10.1002/wrna.1755
   PubMed Web of Science ®Google Scholar
• Su WY, Li JT, Cui Y, et al. Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer. Cell Res. 2012;22(9):1374–1389. doi:10.1038/cr.2012.57
   PubMed Web of Science ®Google Scholar
• Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14(7):723–730. doi:10.1038/nm1784
   PubMed Web of Science ®Google Scholar
• Bu P, Wang L, Chen KY, et al. miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. Nat Commun. 2015;6:6879. doi:10.1038/ncomms7879
   PubMed Web of Science ®Google Scholar
• Vera O, Rodriguez-Antolin C, de Castro J, Karreth FA, Sellers TA, Ibanez de Caceres I. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells. Epigenetics. 2018;13(3):251–263.
   PubMed Web of Science ®Google Scholar
• Li N, Zhan X. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. EPMA J. 2020;11(2):289–309. doi:10.1007/s13167-020-00209-y
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4
   PubMed Web of Science ®Google Scholar
• Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prevent. 2017;18(1):3–9. doi:10.22034/APJCP.2017.18.1.3
   PubMedGoogle Scholar
• Kumari S, Gupta R, Ambasta RK, Kumar P. Multiple therapeutic approaches of glioblastoma multiforme: from terminal to therapy. Biochimica Et Biophysica Acta Rev Cancer. 2023;1878(4):188913. doi:10.1016/j.bbcan.2023.188913
   PubMed Web of Science ®Google Scholar
• POLIVKA JR J, Polivka J, Holubec L, et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme. Anticancer Res. 2017;37(1):21–33. doi:10.21873/anticanres.11285
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.013
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi:10.1016/S0025-6196(11)60735-0
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi:10.21037/tlcr.2016.06.07
   PubMed Web of Science ®Google Scholar
• Cui D, Xie S, Liu Q. Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma. BMC Pulm Med. 2023;23(1):9. doi:10.1186/s12890-023-02305-x
   PubMed Web of Science ®Google Scholar
• Xu L, Li C, Lu H. Invasive mucinous adenocarcinoma of the lung. Transl Cancer Res. 2019;8(8):2924–2932. doi:10.21037/tcr.2019.11.02
   PubMed Web of Science ®Google Scholar
• Cha YJ, Shim HS. Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res. 2017;6(5):508–512. doi:10.21037/tlcr.2017.06.10
   PubMed Web of Science ®Google Scholar
• Ishigaki S, Masuda A, Fujioka Y, et al. Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. Sci Rep. 2012;2(1):529. doi:10.1038/srep00529
   PubMedGoogle Scholar
• Colombrita C, Onesto E, Megiorni F, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem. 2012;287(19):15635–15647. doi:10.1074/jbc.M111.333450
   PubMed Web of Science ®Google Scholar
• Nakaya T, Alexiou P, Maragkakis M, Chang A, Mourelatos Z. FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns. RNA. 2013;19(4):498–509. doi:10.1261/rna.037804.112
   PubMed Web of Science ®Google Scholar
• Ge Z, Cheng Z, Yang X, et al. Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. Cancer Sci. 2017;108(4):653–662. doi:10.1111/cas.13200
   PubMed Web of Science ®Google Scholar
• Xin Y, Shang X, Sun X, Xu G, Liu Y, Liu Y. SLC8A1 antisense RNA 1 suppresses papillary thyroid cancer malignant progression via the FUS RNA binding protein (FUS)/NUMB like endocytic adaptor protein (Numbl) axis. Bioengineered. 2022;13(5):12572–12582. doi:10.1080/21655979.2022.2073125
   PubMed Web of Science ®Google Scholar
• Mukkamalla SKR, Malipeddi D. Myeloma bone disease: a comprehensive review. Int J Mol Sci. 2021;22(12):6208. doi:10.3390/ijms22126208
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Gavriatopoulou M, Dimopoulos MA. Mechanisms of bone destruction in multiple myeloma. Eur J Cancer Care. 2017;26(6):e12761. doi:10.1111/ecc.12761
   Web of Science ®Google Scholar
• Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108(13):3992–3996. doi:10.1182/blood-2006-05-026112
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184. doi:10.1016/j.ceb.2008.12.010
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159–3167. doi:10.1093/emboj/19.13.3159
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303. doi:10.1016/j.ccr.2014.02.025
   PubMed Web of Science ®Google Scholar
• Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras/MAPK signaling research and targeting in blood and solid cancers. Cancers. 2021;13(20):5059. doi:10.3390/cancers13205059
   PubMed Web of Science ®Google Scholar
• Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–359. doi:10.1038/ncb3124
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10(9):671–684. doi:10.1038/nrd3504
   PubMed Web of Science ®Google Scholar
• Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(1):51–64.e59. doi:10.1016/j.cmet.2020.10.012
   PubMed Web of Science ®Google Scholar
• Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22(17):9451. doi:10.3390/ijms22179451
   PubMed Web of Science ®Google Scholar
• Emran TB, Shahriar A, Mahmud AR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652.
   PubMed Web of Science ®Google Scholar